Drug Trial Radar · NCT07459283
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Apr 20, 2026
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Affiliated Hospital of Jiangnan University
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. The dosing schedule and dose could also be adjusted according to the patient's condition. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.
Conditions
- Maligant Solid Tumor
- Head & Neck Cancer
- Thyroid Cancer
- Lung Cancer - Non Small Cell Squamous
- Breast Cancer
- Sarcoma
Interventions
INN805Drug
The drug was administered once every 6 weeks. It was expected that the drug would be administered for 1 to 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine dose-limiting toxicity (DLT)Time frame: 42 days after first dose
- Frequency of adverse events (AEs) and SAEsTime frame: Approximately 12 months
- Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.